14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
TAK vs ELAN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
TAK Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–2 Matrix Metrics)
TAK Overall Winner
6-Pillar Tally: TAK 3 – 2 ELAN (1 Tie)
Matrix Metrics: TAK 8 – 2 ELAN
As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Elanco Animal Health Incorporated (ELAN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas ELAN carries 35.7/100 (SELL) at $26.36 (20.8x Forward P/E, 7.7% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs ELAN. Trailing 12-month operating profitability (TAK 16.6% vs ELAN 7.7%) and valuation multiples (TAK 12.7x vs ELAN 20.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment48.2% of Rev ($12.4B)
90D Engineering Disclosures0 Published
ELAN Moat ProfileCyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $13.2B market capitalization and 7.7% operating margin.
OpEx & R&D Reinvestment48.5% of Rev ($2.50B)
90D Engineering Disclosures0 Published
Investor FAQ TAK vs ELAN Key Questions & Quantitative Answers
As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Elanco Animal Health Incorporated (ELAN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas ELAN carries 35.7/100 (SELL) at $26.36 (20.8x Forward P/E, 7.7% operating margin). Technically, TAK sits in a Markup phase (RSI 73.1, UNCLASSIFIED options structure) and ELAN sits in a Markup phase (RSI 66.9, CONSOLIDATION options structure).
ELAN leads the Growth & Scale pillar: TAK posts +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin), compared with ELAN at +11.3% YoY revenue growth and +440.5% YoY earnings growth on $5.15B TTM revenue (56.2% gross margin, 7.7% operating margin). On trailing 12-month operating scale, TAK generates $25.7B in USD-normalized revenue versus $5.15B for ELAN. In operating R&D and SG&A reinvestment, TAK deploys 48.2% of Rev ($12.4B) (0 90-day corporate R&D disclosures) versus 48.5% of Rev ($2.50B) (0 disclosures) for ELAN.
TAK screens cheaper on headline valuation multiples. TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin), whereas ELAN trades at 20.8x Forward P/E, 19.6x Trailing P/E, 8.94x PEG, and 3.2x EV/Revenue (7.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TAK (0.6% ROE) versus ELAN (-2.2% ROE) capital efficiency.
In options market volatility and institutional positioning, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk). By comparison, ELAN carries 36.1% implied volatility (1st %ile, Compressed (<25th %ile)), a 13.39x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.27β · 49% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.